Hypophysitis that develops in cancer patients treated with monoclonal antibodies blocking cytotoxic T-lymphocyteeassociated protein 4 (CTLA-4; an inhibitory molecule classically expressed on T cells) is now reported at an incidence of approximately 10%. Its pathogenesis is unknown, in part because no pathologic examination of the pituitary gland has been reported to date. We analyzed at autopsy the pituitary glands of six cancer patients treated with CTLA-4 blockade, one with clinical and pathologic evidence of hypophysitis, one with mild lymphocytic infiltration in the pituitary gland but no clinical signs of hypophysitis, and four with normal pituitary structure and function. CTLA-4 antigen was expressed by pituitary endocrine cells in all patients but at different levels. The highest levels were found in the patient who had clinical and pathologic evidence of severe hypophysitis. This high pituitary CTLA-4 expression was associated with T-cell infiltration and IgG-dependent complement fixation and phagocytosis, immune reactions that induced an extensive destruction of the adenohypophyseal architecture. Pituitary CTLA-4 expression was confirmed in a validation group of 37 surgical pituitary adenomas and 11 normal pituitary glands. The study suggests that administration of CTLA-4 blocking antibodies to patients who express high levels of CTLA-4 antigen in the pituitary can cause an aggressive (necrotizing) form of hypophysitis through type IV (T-cell dependent) and type II (IgG dependent) immune mechanisms. (Am J Pathol 2016, 186: 3225e3235; http://dx
Hypophysitis that develops in cancer patients treated with monoclonal antibodies blocking cytotoxic T-lymphocyteeassociated protein 4 (CTLA-4; an inhibitory molecule classically expressed on T cells) is now reported at an incidence of approximately 10%. Its pathogenesis is unknown, in part because no pathologic examination of the pituitary gland has been reported to date. We analyzed at autopsy the pituitary glands of six cancer patients treated with CTLA-4 blockade, one with clinical and pathologic evidence of hypophysitis, one with mild lymphocytic infiltration in the pituitary gland but no clinical signs of hypophysitis, and four with normal pituitary structure and function. CTLA-4 antigen was expressed by pituitary endocrine cells in all patients but at different levels. The highest levels were found in the patient who had clinical and pathologic evidence of severe hypophysitis. This high pituitary CTLA-4 expression was associated with T-cell infiltration and IgG-dependent complement fixation and phagocytosis, immune reactions that induced an extensive destruction of the adenohypophyseal architecture. Pituitary CTLA-4 expression was confirmed in a validation group of 37 surgical pituitary adenomas and 11 normal pituitary glands. The study suggests that administration of CTLA-4 blocking antibodies to patients who express high levels of CTLA-4 antigen in the pituitary can cause an aggressive (necrotizing) form of hypophysitis through type IV (T-cell dependent) and type II (IgG dependent) immune mechanisms. Hypophysitis is a chronic inflammation of the pituitary gland of idiopathic (primary) or known (secondary) etiology.
1 Primary hypophysitis is rare but significant because it enters in the differential diagnosis of other, more common, nonehormone-secreting pituitary masses, such as pituitary adenomas. It typically presents with signs and symptoms of sellar compression and/or various degrees of hypopituitarism. If unrecognized, it can also cause death because of irreversible adrenal insufficiency. Primary hypophysitis encompasses a spectrum of pathologic lesions, 2, 3 ranging from the most common lymphocytic and granulomatous variants to the more recently described xanthomatous, 4 IgG4 plasmacytic, 5 Hypophysitis secondary to the administration of monoclonal antibodies directed against cytotoxic T-lymphocytee associated protein 4 (CTLA-4), a molecule classically expressed on T cells, was first reported in 2003 7 and first reviewed in 2009. 8 This form of hypophysitis is now observed in approximately 10% 9e11 of cancer patients treated with ipilimumab (an IgG1 produced by BristolMyers Squibb, New York, NY). It occurs less frequently in patients receiving tremelimumab (an IgG2 monoclonal antibody against CTLA-4 produced by Pfizer, New York, NY), and rarely in those treated with other immune checkpoint inhibitors, such as antibodies against PD-1, 12 or PD-L1. 13 Overall, however, hypophysitis is the most common endocrine adverse event associated with immune checkpoint inhibitors. 14, 15 In addition, hypophysitis is the most costly adverse event in hospitalized patients with metastatic melanoma, adding an average expense per hospitalization of V10,265 in Spain, V5316 in France, $9735 in Canada, $7231 in Australia, 16 and $8490 in the United States. 17 Since the original report, 7 127 patients have been described in publications as individual case reports or case series (Table 1) . A similar number of patients have appeared as counts, without specific information about their clinical characteristics, in studies of ipilimumab or tremelimumab, as recently reviewed by Bertrand et al 15 in a meta-analysis of 22 clinical trials.
The pathogenesis of hypophysitis secondary to CTLA-4 blockade remains undetermined, a knowledge gap that often Figure S1A) , with a height of 6.08 mm (reference range for sex and age is 4.87 AE 0.95 mm 18 ). On T1-weighted images after contrast, the anterior pituitary contained scattered areas of hypointensity consistent with necrosis (Supplemental Figure S1B) . Diagnoses of hypophysitis and colitis were made on clinical and imaging grounds. The patient began glucocorticoids (hydrocortisone, 100 mg four times per day; and methylprednisolone, 250 mg/day), thyroid hormones (levothyroxine, 75 mg/day), and saline infusions in mid-December. After an initial improvement, she died in January 2015 because of acute respiratory failure. An autopsy was performed.
We then queried the autopsy database of The Johns Hopkins Hospital Pathology Department (searchable electronically from June 1985 to present by authorized personnel) for additional cases and found, as of June 30, 2016 , five metastatic melanoma patients who had received ipilimumab, all at a dose of 3 mg/kg and all without clinical signs and symptoms of hypophysitis.
Autopsy case 2: A 67-year-old man underwent amputation of the third and fourth left toes and sentinel lymph node biopsy in February 2014 for a diagnosis of B-rapidly accelerated fibrosarcoma (BRAF) wild-type melanoma, followed by inguinal, femoral, and pelvic lymph node dissection. Twenty months later, chest and abdominal computed tomographic scans showed enlarged lymph nodes and pulmonary nodules suggestive of metastatic disease, as well as peritoneal carcinomatosis. He began treatment with the antieCTLA-4 antibody ipilimumab and the antiePD-1 antibody nivolumab in October 2015. During follow-up, laboratory studies revealed primary hypothyroidism [decreased free thyroxine: 0.7 ng/dL (reference range, 0.8 to 1.8 ng/dL); and increased thyroid-stimulating hormone: 16.8 UI/L (reference range, 0.5 to 4.5 UI/L)], severe anemia, and coagulopathy. He received treatment with levothyroxine, anticoagulant, and palliative care but died 2 months later because of widely metastatic disease.
Autopsy case 3: A 30-year-old man underwent resection of a left heel tumor in February 2014 that yielded a diagnosis of lentiginous, BRAF-V600 mutant melanoma. Chest and abdominal computed tomographic scans showed multiple pulmonary nodules, accompanied by mediastinal and hilar lymphadenopathy. Lymph node dissection of the left groin revealed metastatic melanoma. The patient began treatment with the BRAF inhibitor dabrafenib. Repeat imaging in September 2014 showed regression of the lung nodules and pelvic lymph nodes, but appearance of renal and subcutaneous metastases. He then began treatment with ipilimumab, which was discontinued after the first dose because of the appearance of autoimmune hepatitis. In November 2014, the patient received the anti-PD1 monoclonal antibody pembrolizumab but developed colitis, requiring the administration of glucocorticoids. He then developed brain metastases and died in March 2015 because of widely metastatic disease.
Autopsy case 4: A 59-year-old man underwent excision of an ulcerating lesion on the left jaw in June 2010. Pathology showed BRAF wild type and cKit L567P mutant melanoma. The patient began therapy with recombinant IL-2 and remained stable until January 2013 when new pulmonary and adrenal nodules were found. He then received one full treatment cycle with ipilimumab (four doses at 3-week intervals) with minimal response. Pembrolizumab was then administered in the winter of 2013, but new metastases to the rib and omentum were found in July 2014. The patient then underwent treatment with recombinant IL-15 but gradually deteriorated because of the appearance of new metastases. He began a new cycle of ipilimumab in December 2014 but died the following month because of aggressive disease.
Autopsy case 5: A 65-year-old man underwent excision of a mass on his left arm that was shown to be BRAF wild-type melanoma in December 2009. Two years later, the lesion recurred and metastasized to the left axillary lymph nodes.
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The patient received one full cycle of ipilimumab (from September to November 2011) with stabilization of disease. The following year, the arm lesion recurred and ipilimumab was re-established. In February 2013, a chest computed tomographic scan revealed bilateral pleural effusion and soft tissue involvement. He received the antiePD-1 antibody nivolumab, initially with partial control of the metastases. The patient then developed renal and heart failure, and died in November 2013 after an acute myocardial infarction.
Autopsy case 6: A 58-year-old man underwent resection of a right flank lesion and dissection of right axilla lymph nodes in January 2013, yielding a diagnosis of metastatic melanoma. In February 2014, because of the presence of multiple pulmonary metastases, he began treatment with ipilimumab and nivolumab, obtaining a partial response that eventually prompted the resection of two residual lung metastases in October 2015. Two months later, however, he developed multiple brain metastases and discontinued the immune checkpoint inhibitors. Despite additional treatments, the disease progressed and caused the patient's demise on May 12, 2016.
Surgical Pathology Pituitary Adenomas
To validate the CTLA-4 immunostainings performed on the six autopsy cases described above, we queried the surgical pathology paraffin block database of The Johns Hopkins Department of Pathology (searchable electronically from March 1984 to present) for pituitary adenomas. Of the total 3274 pituitary surgeries performed in this 33-year interval, 2186 were for pituitary adenomas. We randomly selected 37 specimens, composed of 13 prolactin-secreting, 9 corticotropin-secreting, 8 growth hormoneesecreting, and 7 nonsecreting adenomas.
Normal Pituitary Controls
We also included 11 normal pituitary specimens from autopsy (n Z 7) or surgical pathology (n Z 4) sources. All pituitary specimens were deidentified and analyzed blindly (P.C.) under institutional review board protocol number 04-07-12-05e.
Histologic Stainings Hematoxylin and Eosin and Masson's Trichrome Stains
Pituitary sections were first stained with hematoxylin and eosin and Masson's trichrome to assess morphology and presence of fibrosis.
Immunohistochemistry for Pituitary Hormones and Immunologic Markers
Pituitary sections were then used in immunohistochemistry to detect markers for anterior pituitary hormones, immune cells, immunoglobulins, complement, and CTLA-4.
Anterior pituitary hormones
Antibodies to the six anterior pituitary hormones (growth hormone, prolactin, adrenocorticotropic hormone, thyroidstimulating hormone, luteinizing hormone, and folliclestimulating hormone) were used to characterize the type and frequency of adenohypophyseal cells. Immunostainings were performed on the BenchMark Ultra automated stainer (Ventana Medical System, Tucson, AZ) using routine clinical diagnostic protocols.
Immune cells
Antibodies to CD3 (all T cells), CD4 (helper T cells), CD8 (cytotoxic T cells), CD20 (all B cells), Foxp3 (regulatory T cells), CD138 (plasma cells), and CD68 (macrophages) were used to characterize the immune infiltrate, using automated stainer and routine protocols.
IgG2, IgG1, and complement C4d
To determine whether the injected CTLA-4 blocking antibodies had bound in vivo to the patient's own pituitary gland, we stained the pituitary gland with an antibody against human IgG2 (05-3500; Invitrogen, Carlsbad, CA) or human IgG1 (5218-9850; Serotec, Raleigh, NC). We also stained pituitary sections for C4d (BR-RC4d; ALPCO, Salem, NH), a complement component that binds covalently to surfaces where complement activation is initiated. These experiments were performed manually, with 10-minute antigen retrieval and 30-minute incubations.
CTLA-4
A mouse monoclonal antibody directed against human CTLA-4 (clone 14D3; eBioscience, San Diego, CA) was optimized on the spleen to achieve an optimal signal/noise ratio, which corresponded to a concentration of 2.5 mg/mL. The protocol was then added to the automated stainer and used to analyze our collection of autopsy pituitary sections.
Double indirect immunofluorescence
We used the pituitary gland from autopsy case 6 (which, as discussed in Results, showed pathologic evidence of mild hypophysitis and retained great part of the normal pituitary architecture) to extend our original report of CTLA-4 expression in a subset of prolactin-and thyrotropin-secreting cells. 19 A portion of this gland was frozen in optimal cutting temperature compound, cut (5 mm thick), and double stained for CTLA-4 plus one of the antibodies directed against prolactin, thyroid-stimulating hormone, follicle-stimulating hormone, luteinizing hormone, adrenocorticotropic hormone, or growth hormone (information regarding these antibodies can be found in the study by Iwama et al 19 ). Sections were stained as described by Pollock et al. 20 Then, cells were counted at 40Â to calculate the total number of endocrine cells and, of them, the number of cells positive for the hormone, CTLA-4, or both.
Statistical Analysis
Pituitary CTLA-4 expression was scored on a continuous scale from 0 (no cell stained) to 300 (all cells stained strongly), using the semiquantitative system we previously published. 21 The score was modeled by multiple linear regression using three predictors: diagnostic category (coded as 0 for normal pituitary and 1 for autopsy pituitaries of patients treated with CTLA-4 blocking antibodies), sex, and age. Differences in the proportions of patients with a particular clinical feature when comparing primary to secondary hypophysitis were assessed by Fisher's exact test. Statistical analyses were performed using Stata software release 14 (Stata, College Station, TX).
Results

CTLA-4 Blockade Can Induce a Necrotizing Form of Hypophysitis
The most striking pathologic feature of autopsy case 1 was the near complete destruction of her anterior pituitary gland, because of extensive necrosis (in approximately 30% of the parenchyma) ( Figure 1A ) and fibrosis ( Figure 1B) . Only a few acini of endocrine cells remained in two isolated areas of the gland ( Figure 1A ), which were heavily infiltrated with hematopoietic mononuclear cells (Figure 1, C and D) . The few remaining endocrine cells were mainly of the acidophil class ( Figure 1E ) and growth hormone producing ( Figure 1F) . Prolactin-or adrenocorticotropic hormoneeproducing cells were rare, and gonadotrophs and thyrotrophs absent (data not shown). The posterior pituitary was normal (data not shown), consistent with the absence of central diabetes insipidus in our patients, and the rarity of diabetes insipidus in the published cases [1 (0.9%) of 116] ( Table 1) .
The histologic appearance of the other autopsy cases, who also had received CTLA-4 blockade for the treatment of their melanoma but had not developed clinical or radiological signs of hypophysitis, was that of a normal pituitary gland for cases 2 through 5 (data not shown), and that of mild lymphocytic hypophysitis for case 6 (as presented below).
Evidence of Type IV Hypersensitivity Mechanisms
Type IV hypersensitivity reactions, commonly seen in autoimmune diseases, are mediated by T lymphocytes that cause tissue damage by production of cytokines, activation of B lymphocytes and phagocytes, and direct granzyme/ perforin-mediated cytotoxicity. 22 The pituitary gland of 
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The autopsy of case 6, who had no clinical or radiological signs of hypophysitis, showed pathologic evidence of mild lymphocytic hypophysitis. This consisted of a fine, extravascular presence of lymphocytes scattered throughout the pituitary parenchyma, at times clustered in groups of three to five cells (Supplemental Figure S2A) and associated with loss of the normal endocrine cells (Supplemental Figure S2A) . The infiltrating cells were mainly CD3-positive T cells (Supplemental Figure S2B) .
Evidence of Type II Hypersensitivity Mechanisms
Type II hypersensitivity reactions are mediated by IgG antibodies that bind to antigens expressed on target cells. 22 This binding causes tissue damage by promoting phagocytosis of the target via macrophages and activating the complement cascade. The pituitary gland of the index case was heavily infiltrated with CD68-positive macrophages, which represented the most abundant hematopoietic cell type ( Figure 3A) . Macrophages permeated throughout the entire parenchyma and featured a prominent, vacuolated, foamy cytoplasm ( Figure 3A) . They contained fragments of endocrine cells inside their cytoplasm. For example, remnants of prolactin-secreting cells were observed inside the phagocytic macrophages ( Figure 3B ). Macrophages did not fuse to form multinucleated giant cells or assume the epithelioid appearance typically seen in granulomas.
Staining with an anti-IgG2 antibody revealed in autopsy case 1 the presence of IgG2 on some of the remaining pituitary cells (Figure 3C ), suggesting that the administered tremelimumab (an IgG2 antibody) had bound to its target (CTLA-4) on the pituitary cells. No significant pituitary cell staining was found for IgG1 ( Figure 3C ) or IgG2 in the other autopsy pituitary glands. The complement factor C4d was found to be deposited onto the pituitary cells ( Figure 3D ) and vessels ( Figure 3D ) of the index case. No C4d staining was seen in the other pituitary glands ( Figure 3D ).
Expression of CTLA-4 by Pituitary Endocrine Cells
In autopsy case 1, CTLA-4 protein assessed by immunohistochemistry was expressed strongly in the few remaining pituitary endocrine cells ( Figure 4A ). The expression was cytosolic and granular in appearance ( Figure 4A ). Fragments of CTLA-4epositive endocrine cells were also found inside the infiltrating macrophages ( Figure 4A ), indicating that they had phagocytized pituitary cells expressing CTLA-4.
In the other five melanoma cases treated with ipilimumab, as well as in the 37 pituitary adenomas and 11 normal pituitary controls, the expression of CTLA-4 varied greatly and did not differ among the three groups ( Figure 4B ), even after adjusting for sex, age, and adenoma type (data not shown). In some patients, CTLA-4 was expressed strongly by most pituitary endocrine cells ( Figure 4C ). In others, it was expressed at moderate levels by a subset of pituitary cells ( Figure 4D ).
In others yet, CTLA-4 was not expressed, giving the appearance shown in Figure 4D . In contrast to what is known for regulatory T cells, the expression of CTLA-4 in pituitary endocrine cells seemed independent of Foxp3. This transcription factor, in fact, was not expressed in autopsy case 1 (Supplemental Figure S3A ) and the other pituitary cases (Supplemental Figure S3B) .
Staining the pituitary gland of autopsy case 6, which had minimal lymphocytic infiltration and thus conserved the normal acinar architecture, using antibodies to CTLA-4 and one of the six adenohypophyseal hormones, revealed that CTLA-4epositive cells, as assessed by double immunofluorescence, represented approximately 1.5% of the total endocrine cells (Table 2 ) and included gonadotropin-secreting ( Figure 5 ) and thyrotropinsecreting (data not shown) cells.
Discussion
Hypophysitis secondary to administration of CTLA-4 blocking antibodies is expected to increase in prevalence as the use of cancer immunotherapies grows and diversifies. 23 Several review articles have been published on this topic in recent months. 14, 15, 24, 25 Secondary hypophysitis has features that markedly differ from those of primary hypophysitis, which we have summarized in Table 1 . It predilects males [100 (79%) of 127 published patients versus 287 (29%) of 1005 in primary hypophysitis; P < 0.001] and older ages (59 AE 13 years versus 41 AE 16 years; P < 0.001), in part reflecting the demographics of the underlying cancer. It presents insidiously with vague symptoms referable to cortisol deficiency, which often overlap with those related to cancer. 26 Headache is more common than in primary hypophysitis, but not as severe. Visual disturbances and diabetes insipidus, on the contrary, are extremely rare. At diagnosis, endocrine deficits are pronounced and involve the adrenal, thyroid, and gonadal axes with similar frequencies. Cranial magnetic resonance imaging, almost always abnormal in the primary forms, is normal in approximately a fifth of the cancer patients who develop hypophysitis after CTLA-4 blockade. Overall, hypophysitis secondary to CTLA-4 blockade is difficult to diagnose unless there is a high index of suspicion. Most patients acquire permanent hypopituitarism 27 and cannot discontinue the glucocorticoid replacement because of persistent secondary adrenal insufficiency. 28 Furthermore, glucocorticoids, of proven efficacy in primary hypophysitis, might not be beneficial.
11
The mechanisms underlying the pathogenesis of CTLA4erelated hypophysitis have remained undefined. The present autopsy series suggests that the disease results from a combination of inflammatory and autoimmune mechanisms, schematically summarized in Figure 6 . The early events are likely to be inflammatory type II hypersensitivity reactions: the CTLA-4 antibody administered therapeutically binds to pituitary CTLA-4 antigen, inducing the formation of immune complexes that recruit complement C1q molecules and activate the classic pathway, leading to the formation of products such as C3, C3d, and C4d. These products damage It is informative to speculate on the cellular location of CTLA-4 expression, as it likely relates to the pathogenesis of secondary hypophysitis. In CD4 þ T cells, CTLA-4 is Figure 6 Schematic representation of the mechanism of action of CTLA-4 blocking antibodies. Administration of a CTLA-4 blocking antibody binds to CTLA-4 expressed on T lymphocytes, leading to the beneficial expansion of effector T cells that recognize novel tumor antigens and eliminate the tumor (right side). The same administered antibody, however, also binds to CTLA-4 expressed on pituitary cells, leading to type II and type IV hypersensitivity mechanisms that cause hypophysitis and pituitary cytotoxicity (left side).
found both in the cytosol and on the plasma membrane, depending on the subset of CD4 þ T cells and their functional state. For example, Tai et al 29 have shown by confocal microscopy that in the resting state CTLA-4 is expressed in cytosolic vesicles of the Golgi apparatus in conventional CD4
þ T cells, and in vesicles clustered under the inner side of the plasma membrane in regulatory CD4 þ T cells. On activation through the T-cell receptor, CTLA-4 becomes externalized and found on the outer side of the plasma membrane, as well as released into the extracellular space as soluble CTLA-4. 29 The traditional techniques of immunohistochemistry and immunofluorescence used in this study suggest that in pituitary cells CTLA-4 is found in fine cytosolic granules. If these findings are confirmed with more sensitive techniques, it remains to be demonstrated how antibodies directed against CTLA-4 find their intracellular target. This is an extensively discussed topic in autoimmunity that warrants further studies. For example, in patients with Sjögren syndrome and systemic lupus erythematosus, it remains unknown how antibodies to nuclear antigens (such as Ro/SSA, La/SSB, and doublestranded DNA) penetrate the cell, bind to their cognate antigen, and cause pathologic damage. 30 This study also shows that the expression of pituitary CTLA-4, a T-cell molecule that we reported to be expressed also by pituitary endocrine cells, 19 varies greatly among individuals. In T cells, single-nucleotide polymorphisms in the CTLA-4 gene have been associated with different expression levels of CTLA-4. 31 For example, a substitution at the J030 polymorphism decreased the expression of lymphoid CTLA-4 and related to better response to CTLA-4 blockade in melanoma patients. 32 In pituitary endocrine cells, the expression of CTLA-4 remains to be fully characterized, but we can envision that patients who express the highest levels of pituitary CTLA-4 are those at greatest risk of developing the aggressive form of necrotizing hypophysitis described in case 1 of this autopsy series. CTLA-4 genotyping might therefore help to stratify patients undergoing immunotherapy not only for their response to therapy, 33 but also for their risk of developing hypophysitis.
In summary, we observed type II and IV hypersensitivity reactions and strong CTLA-4 expression in the pituitary gland of a cancer patient who died after CTLA-4 blockade. Our findings are consistent with a disease mechanism wherein administered CTLA-4 antibody binds to pituitary CTLA-4 and initiates a series of cytopathic immune reactions (complement fixation, phagocytosis, and autoreactive lymphocyte activation) that ultimately lead to pituitary pathology and clinical disease.
